IL-1 receptor accessory protein

Target id: 1897

Nomenclature: IL-1 receptor accessory protein

Quaternary Structure: Complexes
Interleukin-1 receptor, type I
Interleukin-33 receptor
Interleukin-36 receptor
Interleukin-1 receptor, type II
Quaternary Structure Comments
IL1RAP is an accessory protein subunit of the functional receptors for IL-1, IL-33 and IL-36. It is a component in three signalling pathways that involve six IL-1 family cytokines (IL-1α, IL-1β, IL-33, IL-36α, IL-36β and IL-36γ).

Gene and Protein Information

Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	References
Human	-	550	3q28	IL1RAP	interleukin 1 receptor accessory protein
Mouse	-	550	16 18.21 cM	Il1rap	interleukin 1 receptor accessory protein
Rat	-	550	11q22	Il1rap	interleukin 1 receptor accessory protein

Previous and Unofficial Names
IL1R3
IL-1R3

Database Links
Alphafold	Q9NPH3 (Hs), Q61730 (Mm), Q63621 (Rn)
CATH/Gene3D	2.60.40.10, 3.40.50.10140
ChEMBL Target	CHEMBL4804256 (Hs), CHEMBL4665591 (Hs)
Ensembl Gene	ENSG00000196083 (Hs), ENSMUSG00000022514 (Mm), ENSRNOG00000001928 (Rn)
Human Protein Atlas	ENSG00000196083 (Hs)
OMIM	602626 (Hs)
Pharos	Q9NPH3 (Hs)
UniProtKB	Q9NPH3 (Hs), Q61730 (Mm), Q63621 (Rn)
Wikipedia	IL1RAP (Hs)

Protein Comments
An anti-IL1RAP monoclonal antibody (CAN04, nidanilimab) has been designed by Cantargia as a novel immunomodulator and it is being evaluated for potential antineoplastic efficacy in patients with solid malignant tumours (Phase 1/2 NCT03267316). CAN04 activates the immune system's killer cells and blocks proliferation signals that promote tumour growth. MAB-hR3, an antagonistic monoclonal antibody that targets IL1RAP inhibits signalling via all three of the signalling pathways in which IL1RAP is a co-receptor, is predicted to offer a novel broad spectrum anti-inflammatory agent for potential treatment of autoimmune and inflammatory diseases, with preclinical evidence provided by a mouse equivalent to MAB-hR3 which attenuates inflammation in in vivo models of inflammatory diseases that are driven by distinct subsets of the IL-1 family cytokines [1].

Protein Comments

An anti-IL1RAP monoclonal antibody (CAN04, nidanilimab) has been designed by Cantargia as a novel immunomodulator and it is being evaluated for potential antineoplastic efficacy in patients with solid malignant tumours (Phase 1/2 NCT03267316). CAN04 activates the immune system's killer cells and blocks proliferation signals that promote tumour growth. MAB-hR3, an antagonistic monoclonal antibody that targets IL1RAP inhibits signalling via all three of the signalling pathways in which IL1RAP is a co-receptor, is predicted to offer a novel broad spectrum anti-inflammatory agent for potential treatment of autoimmune and inflammatory diseases, with preclinical evidence provided by a mouse equivalent to MAB-hR3 which attenuates inflammation in in vivo models of inflammatory diseases that are driven by distinct subsets of the IL-1 family cytokines [1].

References

Show »« Hide

1. Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M et al.. (2019) IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol, 20 (9): 1138-1149. [PMID:31427775]